PT972521E - Composicao farmaceutica contendo estimuladores de interferao gama - Google Patents

Composicao farmaceutica contendo estimuladores de interferao gama

Info

Publication number
PT972521E
PT972521E PT99202497T PT99202497T PT972521E PT 972521 E PT972521 E PT 972521E PT 99202497 T PT99202497 T PT 99202497T PT 99202497 T PT99202497 T PT 99202497T PT 972521 E PT972521 E PT 972521E
Authority
PT
Portugal
Prior art keywords
stimulators
gang
interference
pharmaceutical composition
composition containing
Prior art date
Application number
PT99202497T
Other languages
English (en)
Portuguese (pt)
Inventor
Mark William James Ferguson
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of PT972521E publication Critical patent/PT972521E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
PT99202497T 1995-08-18 1996-08-09 Composicao farmaceutica contendo estimuladores de interferao gama PT972521E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9516967A GB2304342A (en) 1995-08-18 1995-08-18 Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma

Publications (1)

Publication Number Publication Date
PT972521E true PT972521E (pt) 2003-06-30

Family

ID=10779448

Family Applications (2)

Application Number Title Priority Date Filing Date
PT99202497T PT972521E (pt) 1995-08-18 1996-08-09 Composicao farmaceutica contendo estimuladores de interferao gama
PT96927141T PT845007E (pt) 1995-08-18 1996-08-09 Composicao farmaceuica contendo inibidores de interferao-gama

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT96927141T PT845007E (pt) 1995-08-18 1996-08-09 Composicao farmaceuica contendo inibidores de interferao-gama

Country Status (12)

Country Link
EP (2) EP0845007B1 (enExample)
JP (2) JP4070809B2 (enExample)
AT (2) ATE231728T1 (enExample)
AU (1) AU713809B2 (enExample)
CA (1) CA2229590C (enExample)
DE (2) DE69616803T2 (enExample)
DK (2) DK0845007T3 (enExample)
ES (2) ES2164911T3 (enExample)
GB (1) GB2304342A (enExample)
PT (2) PT972521E (enExample)
WO (1) WO1997007136A2 (enExample)
ZA (1) ZA966953B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69927520T2 (de) 1998-12-09 2006-06-22 Protein Design Labs, Inc., Fremont Verwendung von il-12 antikörpern zur behandlung von psoriasis
EP1180037A2 (en) * 1999-05-26 2002-02-20 The Brigham and Women's Hospital Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
JP5530635B2 (ja) * 2007-02-14 2014-06-25 独立行政法人科学技術振興機構 腸管癒着抑制剤
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
RU2539383C1 (ru) * 2013-11-29 2015-01-20 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Фармацевтическая композиция для лечения трофических язв и длительно незаживающих ран различной этиологии в виде мази

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
JPH01502980A (ja) * 1986-06-17 1989-10-12 レイチ，スティーブン　デー ガンマインターフェロンと抗炎症剤または抗発熱剤との組合せ並びに疾患処置方法
NL8700927A (nl) * 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
IL88378A (en) * 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
SG43205A1 (en) * 1988-12-19 1997-10-17 American Cyanamid Co A method for the treatment of endotoxic shock in a mammal
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
ATE132191T1 (de) * 1989-04-19 1996-01-15 Hoffmann La Roche Auflösbare interferon-gamma-rezeptoren sowie verfahren zu deren herstellung
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
JPH05506247A (ja) * 1990-09-27 1993-09-16 シェリング・コーポレーション ヒトγインターフェロンのアンタゴニスト
WO1992014480A1 (en) * 1991-02-22 1992-09-03 Amgen Inc. Use of gm-csf and g-csf to promote accelerated wound healing
NL9101290A (nl) * 1991-07-23 1993-02-16 Stichting Rega V Z W Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
DE4234380A1 (de) * 1992-10-06 1994-04-07 Schering Ag Verwendung von Dopaminagonisten zur Aktivierung des gamma-Interferon-Produktion
AU5669694A (en) * 1992-11-20 1994-06-22 Schering Corporation Antagonists of human gamma interferon
EP0695189B1 (en) * 1992-12-29 1998-11-25 Genentech, Inc. Treatment of inflammatory bowel disease with ifn-gamma inhibitors
JPH09506263A (ja) * 1993-12-09 1997-06-24 アゲット，ミヒェル ＩＦＮ−γレセプターβ−鎖およびその誘導体

Also Published As

Publication number Publication date
ATE208402T1 (de) 2001-11-15
WO1997007136A2 (en) 1997-02-27
DK0972521T3 (da) 2003-05-05
HK1023516A1 (en) 2000-09-15
GB2304342A (en) 1997-03-19
ES2164911T3 (es) 2002-03-01
EP0972521B1 (en) 2003-01-29
ATE231728T1 (de) 2003-02-15
EP0845007B1 (en) 2001-11-07
DE69626050D1 (de) 2003-03-06
JP2007119497A (ja) 2007-05-17
JP4070809B2 (ja) 2008-04-02
PT845007E (pt) 2002-03-28
DK0845007T3 (da) 2001-12-17
AU713809B2 (en) 1999-12-09
ZA966953B (en) 1998-02-16
AU6707196A (en) 1997-03-12
EP0845007A2 (en) 1998-06-03
GB9516967D0 (en) 1995-10-18
DE69626050T2 (de) 2004-01-22
EP0972521A1 (en) 2000-01-19
CA2229590A1 (en) 1997-02-27
JPH11511160A (ja) 1999-09-28
DE69616803D1 (de) 2001-12-13
DE69616803T2 (de) 2002-06-20
JP4616291B2 (ja) 2011-01-19
WO1997007136A3 (en) 1997-08-21
CA2229590C (en) 2010-10-12
ES2192018T3 (es) 2003-09-16

Similar Documents

Publication Publication Date Title
TR199900431T2 (xx) �kame edilmi� siklik amin metaloproteaz inhibit�rleri
CR9879A (es) Moduladores de ccr5 (divisional de la solicitud n° 6392)
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
AP2001002187A0 (en) Piperidines as CCR5 modulators.
ATE286384T1 (de) Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan
CY2295B1 (en) Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents
ATE255589T1 (de) Kristallin form i von clarithromycin
AU8452991A (en) 1-aryl-3-pyridinyl-2-propene-1-ones
PT972521E (pt) Composicao farmaceutica contendo estimuladores de interferao gama
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
DE69626987D1 (de) Pharmaceutische komposition
NO913683D0 (no) Fremgangsmaate for fremstilling av kalsiumopptaksinhibitorer.
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
AU8452791A (en) 1-phenyl-3-aryl-2-propyne-1-ones
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents
ECSP993296A (es) Moduladores de ccr5
ECSP993298A (es) Moduladores de ccr5